1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor

P2Y Receptor

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Related Products (40):

Cat. No. Product Name Effect Purity
  • HY-10064
    Antagonist ≥99.0%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-111557
    Inhibitor ≥99.0%
    YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM.
  • HY-B0606
    Diquafosol tetrasodium
    Agonist ≥99.0%
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium salt
    Agonist ≥98.0%
    Uridine 5′-diphosphoglucose disodium salt (UDP-D-Glucose disodium salt) is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine-5′-diphosphoglucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR.
  • HY-13104
    MRS 2578
    Antagonist ≥98.0%
    MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
  • HY-125989
    2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.
  • HY-125989B
    2-Methylthio-AMP diTEA
    Antagonist ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
  • HY-108660
    PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect.
  • HY-15283
    Inhibitor 99.57%
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-17459
    Clopidogrel hydrogen sulfate
    Inhibitor 99.67%
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
  • HY-W010832
    Uridine-5'-diphosphate disodium salt
    Modulator ≥98.0%
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52 for human P2Y6 receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis.
  • HY-13831
    Antagonist 99.84%
    BPTU (BMS-646786) is a non-nucleotide P2Y1 receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract.
  • HY-19638A
    Cangrelor tetrasodium
    Antagonist 99.93%
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
  • HY-18775
    Inhibitor ≥98.0%
    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).
  • HY-15876
    Clopidogrel thiolactone
    Inhibitor ≥98.0%
    Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.
  • HY-15284
    Inhibitor 99.85%
    Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-15284A
    Prasugrel hydrochloride
    Inhibitor 99.57%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and prodrug, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-15799
    Antagonist 99.11%
    AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.
  • HY-118284
    Inhibitor 98.55%
    Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis, the substrate of carboxylesterase 2 (CES2). Vicagrel demonstrates a favorable safety profile and excellent anti-platelet activity, which could be an anti-platelet drug and for the unmet medical needs of cardiovascular diseases.
  • HY-11021
    Antagonist ≥98.0%
    Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.